The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Gomes, Conrado L R ^a   Leão, Cristina L ^a   Venturotti, Carolina ^a   Barreira, André L ^a   Guimarães, Gabriela ^a   Fonseca, Roberto J C ^a   Fortunato, Rodrigo S ^a   Mourão, Paulo A S ^a   Delgado, Alvimar G ^a   Takiya, Christina M ^a   Leite, Maurilo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; CHONDROITIN SULFATE; COLLAGEN TYPE 18; ENOXAPARIN; GLUCOSE; GLYCOSAMINOGLYCAN; HEPARANASE; HEPARANASE 1; NESTIN; PERLECAN; PROTEOGLYCAN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; COLLAGEN; FUCOSYLATED CHONDROITIN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; CELL INFILTRATION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFICACY; FUCOSYLATION; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ALBUMINURIA; ANIMAL; CELL PROTECTION; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; GLOMERULUS; KIDNEY; METABOLISM; PATHOLOGY; RAT; WISTAR RAT;

MURINAE;

ALBUMINURIA; ANIMALS; CHONDROITIN SULFATES; COLLAGEN; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLYCOSAMINOGLYCANS; KIDNEY; KIDNEY GLOMERULUS; MALE; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 84907000344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106929     Document Type: Article

References (59)

1. Atkins RC, Zimmet P (2010) Diabetic kidney disease: act now or pay later. Nephrol Dial Transplant 25: 331-333.
2. Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010.
3. Haraldsson B, Nyström J, Deen WM (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451-487.
4. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32: 219-226.
5. Jefferson JA, Shanklandand SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 74: 22-36.
6. Kanwar YS, Linker A, Farquhar MG (1980) Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86: 688-693.
7. van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, et al. (1992) A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41: 115-123.
8. Tamsma JT, van den Born J, Bruijn JA, Assmann KJ, Weening JJ, et al. (1994) Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulfate in the glomerular basement membrane. Diabetologia 37: 313-320.
9. Wijnhoven TJ, Lensen JF, Wismans RG, Lamrani M, Monnens LA, et al. (2007) In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria. J Am Soc Nephrol 18: 823-832.
10. Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, Holzman LB, van Kuppevelt TH, et al. (2008) Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 74: 289-299.
11. Goldberg S, Harvey SJ, Cunningham J, Tryggvason K, Miner JH (2009) Glomerular filtration is normal in the absence of both agrin and perlecanheparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant 24: 2044-2051.
12. van den Hoven MJ, Wijnhoven TJ, Li JP, Zcharia E, Dijkman HB, et al. (2008) Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 73: 278-287.
13. Harvey SJ, Jarad G, Cunningham J, Rops AL, van der Vlag J, et al. Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J Pathol 2007; 171: 139-152.
14. Wijnhoven TJ, van den Hoven MJ, Ding H, van Kuppevelt TH, van der Vlaq J, et al. (2008) Heparanase induces a differential loss of heparan sulfate domains in overt diabetic nephropathy. Diabetologia 51: 372-382.
15. Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D Jr, et al. (2005) Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54: 2172-2178.
16. Rops AL, van den Hoven MJ, Veldman BA, Salemink S, Vervoot G, et al. (2012) Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrol Dial Transplant 27: 2853-2861.
17. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F (2011) Heparanase Levels Are Elevated in the Urine and Plasma of Type 2 Diabetes Patients and Associate with Blood Glucose Levels. PLoS One 6: e17312.
18. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61: 208-216.
19. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, et al. (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70: 2100-2108.
20. Garsen M, Rops AL, Rabelink TJ, Berden JH, van der Vlag J (2014) The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant 29: 49-55.
21. Gambaro G, Kong NC (2010) Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J Nephrol 23: 244-252.
22. Pecly IM, Gonçalves RG, Rangel EP, Takiya CM, Taboada FS, et al. (2006) Effects of low molecular weight heparin in obstructed kidneys: decrease of collagen, fibronectin and TGF-beta, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant 21: 1212-1222.
23. Ceol M, Vianello D, Schleicher E, Anglani F, Barbanti M, et al. (2003) Heparin reduces glomerular infiltration and TGF-beta protein expression by macrophages in puromycin glomerulosclerosis. J Nephrol 16: 210-218.
24. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, et al. (1994) Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 46: 797-806.
25. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, et al. (2000) Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11: 2324-2336.
26. Yung S, Chau MK, Zhang Q, Zhang CZ, Chan TM (2013) Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One 8: e54501.
27. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10: 213.
28. Weigert C, Brodbeck K, Häring HU, Gambaro G, Schleicher ED (2001) Lowmolecular- weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 60: 935-943.
29. Bacilieri M, Naggi A, Ceol M, Schleicher ED, Tosetto E, et al. (2011) Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations. Glycobiology 21: 1029-1037.
30. Dedov I, Shestakova M, Vorontzov A, Palazzini E (1997) A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 12: 2295-2300.
31. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlová M, et al. (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13: 1615-1625.
32. Blouza S, Dakhli S, Abid H, Aissaoui M, Ardhaoui I, et al. (2010) Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 23: 415-424.
33. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, et al. (2011) Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 58: 729-736.
34. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, et al. (2012) Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23: 123-130.
35. Gambaro G (2012) Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis 60: 169-170.
36. Mourão PA, Guimarães B, Mulloy B, Thomas S, Gray E (1998) Antithrombotic activity of a fucosylated chondroitin sulfate from echinoderm: sulfated fucose branches on the polysaccharide account for its antithrombotic action. Br J Haematol 101: 647-652.
37. Borsig L, Wang L, Cavalcante MC, Cardilo-Reis L, Ferreira PL, et al. (2007) Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 282: 14984-14991.
38. Melo-Filho NM, Belmiro CL, Gonçalves RG, Takiya CM, Leite M Jr, et al. (2010) Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event? Am J Physiol Renal Physiol 299: F1299-F1307.
39. Chen J, Boyle S, Zhao M, Su W, Takahashi K, et al. (2006) Differential expression of the intermediate filament protein nestin during renal development and its localization in adult podocytes. J Am Soc Nephrol 17: 1283-1291.
40. Mesangial index quantification. Animal Models of Diabetic Complications Consortium (2008) Available: www.amdcc.org/shared/showFile. aspx?doctypeid=3&docid=64. Accessed 19 September 2011.
41. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, et al. (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron 5: 115-132.
42. Weil EJ, Lemley KV, Mason CC, Yee B, Jones Ll, et al. (2012) Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82: 1010-1017.
43. Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634.
44. van den Hoven MJ, Waanders F, Rops AL, Kramer AB, van Goor H, et al. (2009) Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 24: 2637-2645.
45. Ishikawa Y, Kitamura M (1999) Inhibition of glomerular cell apoptosis by heparin. Kidney Int 56: 954-963.
46. Yard BA, Kahlert S, Engelleiter R, Resch S, Waldherr R, et al. (2001) Decreased glomerular expression of agrin in diabetic nephropathy and podocytes, cultured in high glucose medium. Exp Nephrol 9: 214-222.
47. Han J, Hiebert LM. (2013) Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin. Vascular Pharmacology 59: 112-118.
48. Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, et al. (2002) Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GAbinding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 277: 8989-8998.
49. Templeton DM (1989) Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes. Lab Invest 61: 202-211.
50. Girardin EP, Hajmohammadi S, Birmele B, Helisch A, Shworak NW, et al. (2005) Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool. J Biol Chem 280: 38059-70.
51. Edge AS, Spiro RG (2000) A specific structural alteration in the heparan sulphate of human glomerular basement membrane in diabetes. Diabetologia 43: 1056-9.
52. Björson Granqvist A, Ebefors K, Saleem MA, Mathieson PW, Haraldsson B, et al. (2006) Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am J Physiol Renal Physiol 291: F722-F730.
53. Joladarashi D, Salimath PV, Chilkunda ND (2011) Diabetes results in structural alteration of chondroitin sulfate/dermatan sulfate in the rat kidney: effects on the binding to extracellular matrix components. Glycobiology 21: 960-72.
54. Reine TM, Grøndahl F, Jenssen TG, Hadler-Olsen E, Prydz K, et al. (2013) Reduced sulfation of chondroitin sulfate but not heparan sulfation kidneys of diabetic db/db mice. J Histochem Cytochem 61: 606-16.
55. Strunz CM, Matsuda M, Salemi VM, Nogueira A, Mansur AP, et al (2011) Changes in cardiac heparan sulfate proteoglycan expression and streptozotocin-induced diastolic dysfunction in rats. Cardiovasc Diabetol 25; 10: 35.
56. Mogyorosi A, Ziyadeh FN (1998) Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose. Am J Physiol Renal Physiol 275: F827-F832.
57. Rops A, Loeven MA, van Gemst JJ, Eversen I, Van Wijk XM, et al. (2014) Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. Kidney Int Apr 23. doi:10.1038/ki.2014.115.
58. Jeansson M, Granqvist AB, Nyström JS, Haraldsson B (2006) Functional and molecular alterations of the glomerular barrier in long-term diabetes in mice. Diabetologia 49: 2200-2209.
59. Singh A, Fridén V, Dasgupta I, Foster RR, Welsh JE, et al. (2011) High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol Renal Physiol 300: F40-F48.